Respiratory syncytial virus infection
Not recruitingStudy on the Safety and Immune Response of RSVPreF3 OA Vaccine with PCV20 in Adults Aged 60 and Older with RSV Disease
Study on the Safety and Immune Response of RSVPreF3 OA Vaccine with PCV20 in Adults Aged 60 and Older with RSV Disease
- Disease:Respiratory syncytial virus infection
- Substances:GSKVx000000017064Pneumococcal Polysaccharide Serotype 1 Conjugated To Crm197 Adsorbed On Aluminium Phosphate+18
Spain- Participants:18–64 years · 65+ years · Healthy volunteers
- Substances:GSKVx000000017064
- Sponsor:GlaxoSmithKline Biologicals









